<DOC>
	<DOCNO>NCT00564889</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , lenalidomide , may stimulate immune system different way stop plasma cell grow . Drugs use chemotherapy , cyclophosphamide dexamethasone , work different way stop growth plasma cell , either kill cell stop divide . Giving lenalidomide together cyclophosphamide dexamethasone may effective treatment primary systemic amyloidosis . PURPOSE : This phase II trial study well give lenalidomide together cyclophosphamide dexamethasone work treat patient primary systemic amyloidosis .</brief_summary>
	<brief_title>Lenalidomide , Cyclophosphamide , Dexamethasone Treating Patients With Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : Primary * Assess hematologic response rate patient primary systemic amyloidosis treat lenalidomide , cyclophosphamide , dexamethasone . Secondary - Determine organ response rate patient treat regimen . - Determine toxicity regimen patient . - Determine time progression patient treat regimen . - Determine survival patient treat regimen . OUTLINE : Patients receive oral lenalidomide day 1-21 , oral cyclophosphamide* day 1 , 8 , 15 , oral dexamethasone day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . NOTE : *Patients may receive cyclophosphamide 1 year . After completion study treatment , patient follow every 6 month 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histochemical diagnosis AL amyloidosis base detection green birefringent material Congo redstained tissue specimen polarize microscopy Measurable disease , define one following : Serum monoclonal protein ≥ 1.0 g serum electrophoresis Urine monoclonal protein &gt; 200 mg 24hour urine electrophoresis Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Symptomatic organ involvement amyloid justify therapy May include liver involvement , cardiac involvement , renal involvement , grade 1 peripheral neuropathy , soft tissue involvement Must skin purpura carpal tunnel syndrome No amyloidspecific syndrome , carpal tunnel syndrome skin purpura , evidence disease Vascular amyloid bone marrow biopsy specimen plasmacytoma indicative systemic amyloidosis No clinically overt multiple myeloma ( i.e. , monoclonal BMPC &gt; 30 % , bone lesion , hypercalcemia ) PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,000/μL Platelet count ≥ 75,000/μL Creatinine &lt; 3.0 mg/dL Not pregnant Negative pregnancy test Fertile patient must use two acceptable method contraception ≥ 28 day prior , , ≥ 28 day completion study treatment No nursing ≥ 28 day completion study treatment No blood , semen , sperm donation ≥ 28 day completion study treatment No malignancy within past 5 year except treat basal cell squamous cell carcinoma skin , carcinoma `` situ '' cervix breast No neuropathy ≥ grade 2 , define motor neuropathy ( symptomatic weakness interfere function , interfere activity daily live [ ADL ] ) sensory neuropathy ( sensory alteration paresthesia [ include tingle ] , interfere function , interfere ADL ) No uncontrolled infection No syncope within past 30 day No known hypersensitivity thalidomide , include desquamate rash thalidomide past No known seropositivity HIV No active hepatitis A , B , C No New York Heart Association class III IV heart disease No venous thromboembolic event within past 42 day Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation Patients intolerant aspirin may use low molecular weight heparin PRIOR CONCURRENT THERAPY : No prior lenalidomide More 2 week since prior concurrent anticancer agent treatments More 4 week since prior experimental agent No concurrent corticosteroid except chronic steroid ( maximum dose 20 mg/day prednisone equivalent ) disorder amyloidosis ( e.g. , adrenal insufficiency rheumatoid arthritis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>